OREANDA-NEWS. According to the results of the first quarter of 2014 total sales of the top five best selling Rx drugs amounted to RUR 445.0 million, which corresponds to 46.9% of sales in the Rx drugs segment and 33.9% [1] of the Company's total sales.

According to the results of the first quarter of 2014 the top five best selling Rx drugs are:

Geptor (Ademetionine; ATC[2] "Digestive tract and metabolism"); 21.8% of sales in the Rx drugs segment;

Cerepro (Choline Alfoscerate; ATC "Medications for the treatment of the nervous system diseases"); sales in the segment made 9.6%;

Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 6.9%;

Anfibra (Enoxaparin sodium; ATC "Medications affecting hematogenesis and blood"); sales in the segment made 4.9%;

Parclitaxel-LENS (Parclitaxel; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 3.7%;

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. Total sales of the top five best selling OTC drugs amounted to RUR 184.4 million, which corresponds to 98.8% of sales in the OTC drugs segment and 14.1% of the Company's total sales

According to the results of the first quarter of 2014 the top five best selling medicines are as follows:

Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales in the OTC drugs segment made 65.1%;

Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 18.6%;

Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales in the segment made 9.7%;

Vitasharm and Vitatress (ATC "Vitamins"); sales in the segment made 4.4%;

Ginkgo biloba (Ginkgo biloba; ATC "Medications for the treatment of urogenital organs"); sales in the OTC drugs segment made 1.0%.

Traditional drugs segment

Total sales of the top four best selling drugs amounted to RUR 2.2 million, which corresponds to 100.0% of sales in the segment and 0.2% of the Company's total sales.

According to the results of the first quarter of 2014 the top four best selling medicines are as follows:

Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs for systematic use"); sales in the traditional drugs segment made 34.9%;

Pyridoxine (ATC "Alimentary tract and metabolism"); sales in the segment made 24.3%;

Vero-Ciprofloxacin (Ciprofloxacin; ATC "Antimicrobials for systematic use"); sales in the segment made 23.4%;

Vero-Loperamide (Loperamide; ATC "Alimentary tract and metabolism"); sales in the segment made 17.4%;

Non-pharamaceutical products

Total sales of the top five best selling OTC drugs amounted to RUR 171.2 million, which corresponds to 98.4% of sales in the segment and 13.1% of the Company's total sales.

According to the results of the first quarter of 2014 the top five best selling medicines are as follows:

Conventional antimicrobial adhesive bandages; 30.7% of sales in the segment;

Therapeutic patches - corn plasters; 29.2% of sales in the segment;

Conventional reel adhesive bandages; 22.1% of sales in the segment;

Therapeutic patches - pepper plasters; 13.2% of sales in the segment;

Comida (ATC "Nutritional therapy"); 3.3% of sales in the segment.

NEW DRUGS PRODUCTION AND SALES

In the first quarter of 2014 Veropharm initiated production and sales of new forms and dosages of the following drugs:

"Nutrico Dietо" (dietary products for weight control)

Veroplast (Antibacterial waterproof plaster 6x10 №75)

NEW DRUGS REGISTRATION

In the first quarter of 2014 Veropharm received registration for wet napkins for intimate hygiene "Sensex".

At present 39 products are in the development plan and 24 of them are currently at different stages of the registration process.

In the first quarter of 2014 Veropharm received registration for the following four products produced by LLC "LENS-Pharm":

Geptor (Ademetionine; ATC "Digestive tract and metabolism");

Vero-fludarabine (Fludarabine; ATC "Antineoplastic and immunomodulating agents, Antimetabolite, Purine analogue");

Fluorouracil-LENS (Fluorouracil, ATC "Antineoplastic and immunomodulating agents, Antimetabolite");

Etoposide (Etoposide, ATC "Antineoplastic and immunomodulating agents, Alkaloid").

At present 10 products are in the registration process in CIS countries: 5 in Kazakhstan, 5 in Mongolia.